Paion has taken an important step towards its goal of US approval for its ultra-fast-acting sedative, remimazolam with the announcement of positive top line results from a safety study in high risk colonoscopy patients. It is approaching another important milestone, with the confirmatory Phase III in bronchoscopy patients expected to complete recruitment soon; top line results are likely about two months later. Paion is on track to file for approval in both the US (in procedural sedation via partner Cosmo Pharmaceuticals) and Japan (for general anaesthesia) by mid-2018.

Continue reading

This version is programmatically created by Research Central and qualified in its entirety to the original PDF.

Powered by Research Central